Clinical trials: Intravenous Infusions
Neoplasms
Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors
This is a two-part study of a compound called PF-05212384 (also known as PKI-587). The purpose of part 1 is to identify the Maximum Tolerated Dose (MTD) of PF-05212384 using a Continual Reassessment Method (CRM).
- Trial name
- B2151001 (NCT00940498)
- Testing
- PF-05212384 (also known as PKI-587)
- Where
- 9 sites in United States, Spain and 1 more
- Volunteers
- 78 people
- Sponsor
- Pfizer
Acute Bacterial Skin and Skin Structure Infection (ABSSSI), Prosthetic Joints Infection (PJI)
Phase 1, Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants
This is a phase 1, single-center, randomized, double-blind, placebo-controlled, dose-escalation clinical trial of single and multiple intravenous doses of TNP-2092 for injection in healthy Chinese participants.
- Trial name
- NCT06394518
- Testing
- TNP-2092 for injection
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- TenNor Therapeutics Inc.
IV Infiltration, IV Extravasation
Assessment Intravenous Site Events During Outpatient Infusion Procedures With a Wireless Thermal Measurement Device During
This study evaluates a Non-invasive Thermal Infusion Site Monitor (NTISM) device when used during routine outpatient infusion treatments.
- Trial name
- NCT07009405
- Testing
- non-invasive thermal infusion site monitoring NTISM device
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Rhaeos, Inc.
Healthy
Single Dose Study of PF-05230907 in Healthy Japanese Subjects
The purpose of this study is the following: To determine the safety and tolerability of single ascending intravenous (IV) doses of PF-05230907 in healthy Japanese subjects.
- Trial name
- NCT02537002
- Testing
- PF-05230907
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tumors
AZD1152 in Patients With Advanced Solid Malignancies
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 48-hour infusion every 14 days and as a 2-hour infusion for 2 consecutive days every 14 days in patients…
- Trial name
- NCT00338182
- Testing
- AZD1152 part A, AZD1152 part B
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants
The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics with intravenous(IV) administration of IRX-010 in Healthy Participants.
- Trial name
- NCT06356259
- Testing
- IRX-010
- Where
- Netherlands
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- ImmunoRx Pharma Inc.
Cardiac Failure, Myocardial Failure
An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic
The purpose of this study is to investigate continuous 8-hour introductions of BMS-986231 in participants with heart failure and weakened heart function given a standard dose of diuretic.
- Conditions
- Cardiac Failure, Myocardial Failure, Congestive Heart Failure, Heart Decompensation
- Trial name
- NCT03730961
- Testing
- BMS-986231, Furosemide
- Where
- 2 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- Bristol-Myers Squibb
Asthma
A Single Ascending Dose Study of R1671 in Patients With Mild Intermittent Asymptomatic Asthma.
This 8 arm study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of R1671 or placebo in patients with mild, intermittent, asymptomatic asthma.
- Trial name
- NCT00517816
- Testing
- RG1671
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Healthy Volunteer
A Study of Three Modified-Release Formulations of RO4917523 in Healthy Volunteers
This single-center, open label, randomized, 3-period cross-over study will compare 3 modified-release formulations of RO4917523 in healthy volunteers.
- Trial name
- NCT01873508
- Testing
- RO4917523
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis
A Trial of SHR - 1906 in Healthy Subjects
This study is a phase 1 single dose escalation study of SHR-1906 in healthy subjects. The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of SHR-1906 in healthy subjects.
- Trial name
- NCT04986540
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Healthy Volunteers
An Absolute Bioavailability Study in Healthy Participants Comparing Oral to Intravenous Administration of GDC-0973 (Cobimetinib)
The primary objective of Part 1 of this study is to evaluate the safety and tolerability of the intravenous (IV) dose of GDC-0973.
- Trial name
- NCT01249118
- Testing
- GDC-0973 IV Infusion, GDC-0973 Oral Capsules
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis
Phase 1b/2 Study of IV Sarilumab in Adult With RA
This is a Phase 1/Phase 2 study with: 5-arms design for Part A; and a single arm for Part B. The purpose of this study is to measure PK parameters and safety with sarilumab intravenous (IV) with or without concomitant oral…
- Trial name
- OPALS (NCT07704580)
- Testing
- Sarilumab, SAR153191 SC, Sarilumab, SAR153191 IV
- Where
- 12 sites in United States
- Volunteers
- 140 people
- Sponsor
- Sanofi
Autoimmune Diseases
Safety and Tolerability of GX-P1 in Healthy Male Volunteers
This study is a single-center, double-blind, placebo-controlled, phase I study with healthy male volunteers receiving ascending single dose of GX-P1
- Trial name
- NCT04298749
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Genexine, Inc.
OIC
TD-1211 IV/Oral Mass Balance Study
The purpose of this study is to determine TD-1211 is processed by the body.
- Trial name
- NCT01702194
- Testing
- TD-1211 IV [C14], TD-1211 PO [C14]
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Glycyx Therapeutics
Safety, Tolerability
Phase I, Single Centre, Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043
Phase I, Single Centre, Open Label Study to Assess the Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 after aSingle Ascending Bolus Dose Followed by a Single Infusion Dose in Elderly(=65 years)…
- Conditions
- Safety, Tolerability, Pharmacokinetics, Sedation
- Trial name
- AZD3043 (NCT01086813)
- Testing
- AZD3043
- Volunteers
- healthy volunteers welcome
- Sponsor
- AstraZeneca
Human Immuno-deficiency Virus (HIV) Disease
A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382
Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic disease requiring lifelong therapy.
- Trial name
- NCT06032546
- Testing
- Budigalimab, ABBV-382
- Where
- 80 sites in United States, Belgium and 11 more
- Volunteers
- 163 people
- Sponsor
- AbbVie
Metastatic Uveal Melanoma in the Liver
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
This study is an open-label, phase 1/1b study of the pressure-enabled hepatic artery infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with metastatic uveal melanoma.
- Trial name
- NCT04935229
- Testing
- SD-101, Nivolumab, Ipilimumab
- Where
- 10 sites in United States
- Volunteers
- 67 people
- Sponsor
- TriSalus Life Sciences, Inc.
COVID-19
Zofin to Treat COVID-19 Long Haulers
The purpose of this study is to assess the safety and potential efficacy of Zofin administered intravenously in subjects experiencing prolonged symptoms (> 6 weeks and < 24 months) of COVID-19.
- Trial name
- NCT05228899
- Testing
- Zofin
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- ZEO ScientifiX, Inc.
Healthy
Single Ascending Dose Study of Intravenous Infusion of PF 07304814 in Healthy Adult Participants
The current study is the second clinical administration with PF-07304814, the phosphate prodrug of the active moiety PF-00835231, and the first in healthy adult participants.
- Trial name
- NCT04627532
- Testing
- PF-07304814
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Epilepsy
Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy
Keppra injection is approved in the US as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy.
- Trial name
- NCT00505934
- Testing
- Levetiracetam
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 19 people
- Sponsor
- UCB Pharma SA